Results 101 to 110 of about 7,681 (165)

Clinical use of CCR5 inhibitors in HIV and beyond

Journal of Translational Medicine, 2010
Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for treatment and prevention of HIV infection.
Gilliam Bruce, Riedel David, Redfield Robert   +2 more
doaj  

CCR5 blockade inhibits menstrual-driven proinflammatory T cell infiltration into the cervicovaginal mucosa of women. [PDF]

Sci Adv
Swaims-Kohlmeier A, Vidal P, Varughese R, Hardnett FP, Daniel GA, Garcia-Lerma JG, Ofotokun I, Sheth AN.   +7 more
europepmc   +1 more source

T cell-derived CCL5 drives macrophage immunometabolic remodeling in chronic prostatitis via the CCR5-ERK-PKM2/HIF-1α axis. [PDF]

Redox Biol
Liu X, Li B, Dou X, Ju W, Liu W, Zhang F, Jin C, Lu Y, Wang R, Chen X, Liang C, Zhang M.   +11 more
europepmc   +1 more source

Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial. [PDF]

BMJ Open
Broc N, Byczynski G, Dirren E, Carrera E.   +3 more
europepmc   +1 more source

Donor macrophage depletion permits posttransplant tolerance induction in a murine islet transplant model. [PDF]

Am J Transplant
Dilts M, Fay OK, Yu Y, Jordan CZ, Luo X.
europepmc   +1 more source

CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma. [PDF]

J Transl Med
Tan M, Chen Y, Yang J, Wang Q, Li L.
europepmc   +1 more source

Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection

, 2008
Background We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment- Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of ...
Raffi, F, Westby, M, Nelson, M, van der Ryst, E, Lazzarin, A, Tebas, P, Hoepelman, AIM, Bellos, N, Dunne, MW, Sullivan, JF, Fatkenheuer, G, Hirschel, B, Saag, M, Ridgway, C, Mayer, H, Lampiris, H, Konourina, I, Felstead, S, Cooper, DA, Tawadrous, M, Trottier, B   +20 more
core  

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. [PDF]

Oncoimmunology
Rosado-Sanz M, Martínez-Alarcón N, Meel MH, Rius-Perez S, Tolboom ZJ, Salvador-Coloma C, Burgos-Panadero R, Coronado E, Montoliu G, Casals E, Esteve-Codina A, Ripoll F, Santaballa A, Font de Mora J.   +13 more
europepmc   +1 more source

Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. [PDF]

Signal Transduct Target Ther
Suarez-Carmona M, Hampel M, Zhang XW, Pöchmann A, Grauling-Halama SA, Valous NA, Charoentong P, Ferber D, Wissfeld J, Höflich A, Goriely S, Detavernier A, Azouz A, Rongvaux A, Zukunft S, Fleming I, Okun JG, Baracos V, Heikenwalder M, Zitvogel L, Xu X, Xu C, Volkmar M, Schraivogel D, Steinmetz L, Hamanishi J, Mandai M, Gaida M, Mokry T, Nattenmüller J, Sedlaczek O, Monje N, Schwab R, Hasenburg A, Mavratzas A, Boger RJ, Marmé F, Schott S, Halama N.   +38 more
europepmc   +1 more source

Selected Chemokines as Prognostic Biomarkers and Therapeutic Targets in Ovarian Cancer. [PDF]

Curr Issues Mol Biol
Długaszek A, Kabut J, Domagała-Haduch M, Gorzelak-Magiera A, Sadurska J, Morawiec ML, Mielczarek-Palacz A, Gisterek-Grocholska I.   +7 more
europepmc   +1 more source